Halabi S, et al. - Researchers undertook this investigation to assess the overall survival (OS) in black vs white men with metastatic castration-resistant prostate cancer (mCRPC) treated in phase 3 clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen. They combined individual participant data from 8,820 men with mCRPC randomized in nine phase 3 trials to DP or a DP-containing regimen. Outcomes suggested a statistically significant higher OS in black vs white men with mCRPC who were enrolled in these clinical trials after adjusting for known prognostic factors.